{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:44:42Z","timestamp":1785833082494,"version":"3.56.0"},"reference-count":50,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014483","name":"National Pharmaceutical Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["INQUIRY"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>The 340B Drug Pricing Program aims to help facilities serving low-income and uninsured patients to stretch scarce resources by allowing covered entities to purchase outpatient drugs at federally mandated discounted rates while often receiving reimbursement for them at higher rates by commercial payers and Medicare. Despite increasing focus on the expansion and impact of the program, profit margins under 340B have not been fully explored. We aimed to examine drug-, facility-, and geographic-level factors that influence drug margins among 340B covered entities. We conducted a cross-sectional analysis of predictors of facility-level 340B margins for 5 drug classes in a multivariable regression model using 2021 data linked across multiple proprietary and public datasets. Regression results show that drug, facility characteristics, and geographic healthcare market-level characteristics influence drug margins under the 340B program. Adjusted 340B margins were higher in hospital outpatient departments than free-standing offices (ie, hospital-affiliated physician offices and independent, 340B eligible clinics) and among covered entities in more concentrated (ie, less competitive) markets. Covered entity market power, quantified by a facility-level measure of non-340B drug margins indicating pricing power, and area wealth were both associated with higher 340B drug margins. Margins on 340B drugs were higher among facilities in stronger bargaining positions and those serving wealthier areas. These findings add to the growing body of literature on expansions of the 340B program into more affluent communities, informing calls for reforms to ensure the 340B program serves low-income and uninsured patients.<\/jats:p>","DOI":"10.1177\/00469580251324051","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T02:41:44Z","timestamp":1742784104000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Association of 340B Program Drug Margins with Covered Entity Characteristics"],"prefix":"10.1177","volume":"62","author":[{"given":"Robert J.","family":"Nordyke","sequence":"first","affiliation":[{"name":"Petauri LLC, formerly National Pharmaceutical Council, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Motyka","sequence":"additional","affiliation":[{"name":"National Pharmaceutical Council, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Patterson","sequence":"additional","affiliation":[{"name":"National Pharmaceutical Council, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Neuman K Ray N. Initial findings from analysis of Medicare Part B payment rates and 340B ceiling prices. Medicare Payment Advisory Commission. Published October 2023. Accessed January 17 2025. https:\/\/www.medpac.gov\/wp-content\/uploads\/2023\/10\/340B-ceiling-prices-April-2024-SEC.pdf"},{"key":"e_1_3_3_3_2","unstructured":"Berkeley Research Group. 340B Program at a Glance. Published January 2024. Accessed January 17 2025. https:\/\/media.thinkbrg.com\/wp-content\/uploads\/2024\/01\/12123932\/340B-Program-at-a-Glance_2024-FINAL-CLEAN.pdf"},{"key":"e_1_3_3_4_2","unstructured":"Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Patient and Entity Eligibility. Health Resources and Services Administration. October 24 1996. Accessed 1\/17\/26. https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/opa\/patient-entity-eligibility-10-24-96.pdf"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14141"},{"key":"e_1_3_3_6_2","unstructured":"Government Accountability Office. Drug pricing: manufacturer discounts in the 340B program offer benefits but federal oversight needs improvement. 2011. https:\/\/www.gao.gov\/assets\/gao-11-836.pdf"},{"key":"e_1_3_3_7_2","unstructured":"General Accounting Office. 340B Drug Discount Program: Information about Hospitals That Received an Eligibility Exception as a Result of COVID-19. (GAO Publication GAO-23-106095). Washington D.C.: U.S. Government Printing Office. 2023. https:\/\/www.gao.gov\/assets\/gao-23-106095.pdf"},{"key":"e_1_3_3_8_2","unstructured":"Fein AJ. Exclusive: the 340B program hits $16.2 billion in 2016; now 5% of U.S. drug market. Drug Channels. May 18 2017. http:\/\/www.drugchannels.net\/2017\/05\/exclusive-340b-program-hits-162-billion.html"},{"key":"e_1_3_3_9_2","unstructured":"Health Resources and Services Administration. 2021 340B Covered Entity Purchases. 2021. https:\/\/www.hrsa.gov\/opa\/updates\/2021-340b-covered-entity-purchases"},{"key":"e_1_3_3_10_2","unstructured":"Fein AJ. The 340B Program Reached $54 Billion in 2022\u2014Up 22% vs. 2021. September 24 2023. https:\/\/www.drugchannels.net\/2024\/10\/the-340b-program-reached-66-billion-in.html#:~:text=For%202023%2C%20discounted%20purchases%20under %2457.8%20billion%20(%2B%245.5%20billion)"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.2139"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3716"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3360"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13281"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14204"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35262"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0540"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.2015"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88761"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13278"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.0833"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2306609"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31158"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.6445"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18145"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1215\/03616878-10041219"},{"issue":"8","key":"e_1_3_3_27_2","first-page":"868","article-title":"Estimated discounts generated by Medicare drug negotiation in 2026","volume":"29","author":"Hernandez I","year":"2023","unstructured":"Hernandez I, Gabriel N, Dickson S. Estimated discounts generated by Medicare drug negotiation in 2026. J Manag Care Spec Pharm. 2023;29(8):868-872.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_3_28_2","unstructured":"U.S. Census Bureau. American Community Survey 1-Year Estimates. Ratio of Income to Poverty Level of Families in the Past 12 Months. 2021. https:\/\/www.census.gov\/programs-surveys\/acs\/data.html"},{"key":"e_1_3_3_29_2","unstructured":"US Census Bureau. Annual Resident Population Estimates for Metropolitan and Micropolitan Statistical Areas and Their Geographic Components for the United States: April 1 2020 to July 1 2022 (CBSA-EST2022). https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2020s-total-metro-and-micro-statistical-areas.html"},{"key":"e_1_3_3_30_2","unstructured":"CMS. Market Saturation & Utilization Core-Based Statistical Areas Mapping Tool. https:\/\/data.cms.gov\/tools\/market-saturation-utilization-core-based-statistical-areas-mapping-tool"},{"key":"e_1_3_3_31_2","unstructured":"CBSAs consist of the county or counties (or equivalent entities) associated with at least one core (urban area) of at least 10 000 population plus adjacent counties having a high degree of social and economic integration with the core as measured through commuting ties. https:\/\/www.census.gov\/programs-surveys\/metro-micro\/about\/glossary.html#:~:text=Core%20Based%20Statistical%20Areas%20(CBSAs) -Refer%20collectively%20to&text=CBSAs%20consist%20of%20the%20county as%20measured%20through%20commuting%20ties"},{"key":"e_1_3_3_32_2","unstructured":"To access the Appendix click on the Details tab of the article online."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1706475"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.00812"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1201268"},{"issue":"4","key":"e_1_3_3_36_2","first-page":"1","article-title":"Why are hospital prices rising?","volume":"1","author":"Ho V","year":"2013","unstructured":"Ho V, Dugan J, Ku-Goto MH. Why are hospital prices rising? Health Manag Policy Innov. 2013;1(4):1-16.","journal-title":"Health Manag Policy Innov"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(98)00036-8"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-6296(92)90001-h"},{"key":"e_1_3_3_39_2","unstructured":"Conti RM Landrum MB Jacobson M. The impact of provider consolidation on outpatient prescription drug based cancer care spending. Health Care Cost Institute. Published online 6\/3\/2016. Accessed 1\/14\/25. https:\/\/www.siteneutral.org\/wp-content\/uploads\/2016\/06\/3_HCCI-Issue-Brief-Impact-of-Provider-Consolidation.pdf"},{"key":"e_1_3_3_40_2","unstructured":"Vandervelde A. 340B growth and the impact on the oncology marketplace. http:\/\/communityoncology.org\/pdfs\/BRG_COA_340B-Report_9-15.pdf"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2018.04.001"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.4610"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.18.3.167"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1435"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2023.89377"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1356"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2303245"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12691"},{"key":"e_1_3_3_49_2","article-title":"The 340B program: mandatory reporting, alternative eligibility criteria should be top priorities for congress","author":"Nikpay S","year":"2017","unstructured":"Nikpay S, Buntin MB, Conti RM. The 340B program: mandatory reporting, alternative eligibility criteria should be top priorities for congress. Health Affairs Blog. Published online October 10, 2017. doi:10.1377\/hblog20171021.982593.","journal-title":"Health Affairs Blog"},{"key":"e_1_3_3_50_2","unstructured":"Mulligan K. The 340B Drug Pricing Program: Background Ongoing Challenges and Recent Developments. October 14 2021. https:\/\/schaeffer.usc.edu\/wp-content\/uploads\/2024\/10\/USC_Schaeffer_340BDrugPricingProgram_WhitePaper.pdf"},{"key":"e_1_3_3_51_2","unstructured":"Vandervelde A Erb K Hurley L. For-Profit Pharmacy Participation in the 340B Program. October 2020. https:\/\/media.thinkbrg.com\/wp-content\/uploads\/2020\/10\/06150726\/BRG-ForProfitPharmacyParticipation340B_2020.pdf"}],"updated-by":[{"DOI":"10.1177\/00469580261450809","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000}}],"container-title":["INQUIRY: The Journal of Health Care Organization, Provision, and Financing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00469580251324051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00469580251324051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00469580251324051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:10:08Z","timestamp":1777461008000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00469580251324051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":50,"alternative-id":["10.1177\/00469580251324051"],"URL":"https:\/\/doi.org\/10.1177\/00469580251324051","relation":{},"ISSN":["0046-9580","1945-7243"],"issn-type":[{"value":"0046-9580","type":"print"},{"value":"1945-7243","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"article-number":"00469580251324051"}}